Optimization of lentiviral vectors generation for biomedical and clinical research purposes: Contemporary trends in technology development and applications

Current Gene Therapy

Volumn 11, Issue 2, 2011, Pages 144-153

  Kumar, Pankaj ^a   Woon Khiong, Chan ^b  

^a NATIONAL ENVIRONMENT AGENCY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biosafety; Gene transfer; Haematopoietic stem cells (HSCs); IDLVs; Induced pluripotent stem cells (iPSCs); Lentiviral vector (LV); SINLVs; Split genome approach

Indexed keywords

ALD PROTEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA GLOBIN; BLOOD CLOTTING FACTOR 9; CHEMOKINE RECEPTOR CCR5; CRE RECOMBINASE; DNA BINDING PROTEIN; DNA DIRECTED RNA POLYMERASE; DOXYCYCLINE; ECDYSONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE 5' TRIPHOSPHATE CYCLOHYDROLASE 1; GUANOSINE TRIPHOSPHATE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; KRUPPEL LIKE FACTOR 4; LENTIGLOBIN; LENTIVIRUS VECTOR; LEXGENLEUCEL T; MIFEPRISTONE; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROSAVIN; PROTEIN; RAPAMYCIN; SHORT HAIRPIN RNA; TAMOXIFEN; TETRACYCLINE; TRANSCRIPTION FACTOR SOX2; TRIPARTITE MOTIF PROTEIN 5; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VRX 1273; VRX 496; ZINC FINGER NUCLEASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BETA THALASSEMIA; BIOSAFETY; CLINICAL RESEARCH; GENE TRANSFER; GENETIC DISORDER; HEMOPHILIA B; HUMAN; INFECTION; LOXP SITE; MEDICAL RESEARCH; MUTAGENESIS; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PLURIPOTENT STEM CELL; REVIEW; THERAPY EFFECT; TRANSACTIVATION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS REPLICATION; ADRENOLEUKODYSTROPHY; ANIMAL; BETA-THALASSEMIA; CYTOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM;

ADRENOLEUKODYSTROPHY; ANIMALS; BETA-THALASSEMIA; BIOMEDICAL RESEARCH; GENE THERAPY; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LENTIVIRUS; GENETIC THERAPY;

EID: 79953023267     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652311794940782     Document Type: Review

References (141)

1. D'Costa J, Mansfield SG, Humeau LM. Lentiviral vectors in clinical trials: Current status. Curr Opin Mol Ther 2009; 11: 554-64.
2. Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther 2008; 8: 181-190.
3. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60: 249-271.
4. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2- associated clonal T cell proliferation in two patients after genetherapy for SCID-X1. Science 2003; 302: 415-419.
5. Hammond SM, Crable SC, Anderson KP. Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk Res 2005; 29: 89-97.
6. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363:355-364.
7. Marwick C. FDA halts gene therapy trials after leukaemia case in France. BMJ 2003; 326: 181.
8. http://www.wiley.com/legacy/wileychi/genmed/clinical/
9. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006; 103: 17372-17377.
10. Manilla P, Rebello T, Afable C, et al. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 2005; 16: 17-25.
11. Sinn PL, Sauter SL, McCray PB, Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther 2005; 12: 1089-1098.
12. Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 2010; 24: 177-192.
13. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005; 16: 1241-1246.
14. Felice B, Cattoglio C, Cittaro D, et al. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One 2009; 4: e4571.
15. Laufs S, Guenechea G, Gonzalez-Murillo A, et al. Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med 2006; 8: 1197-1207.
16. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther 2008; 8: 419-429
17. Hombrouck A, De Rijck J, Hendrix J, et al. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog 2007; 3: e47.
18. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11388.
19. Farson D, Witt R, McGuinness R, et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12: 981-997.
20. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviralvectors. Mol Ther 2001; 3: 97-104.
21. Ikeda Y, Takeuchi Y, Martin F, et al. Continuous high-titer HIV-1vector production. Nat Biotechnol 2003; 21: 569-572.
22. Ni Y, Sun S, Oparaocha I, et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 2005; 7: 818-834.
23. Loew R, Meyer Y, Kuehlcke K, et al. A new PG13-based packaging cell line for stable production of clinical-grade selfinactivating gamma-retroviral vectors using targeted integration. Gene Ther 2010; 17: 272-280.
24. Broussau S, Jabbour N, Lachapelle G, et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 2008; 16: 500-507.
25. Throm RE, Ouma AA, Zhou S, et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009; 113:104-110.
26. Lesch HP, Turpeinen S, Niskanen EA, et al. Generation of lentivirus vectors using recombinant baculoviruses. Gene Ther 2008; 15: 1280-1286.
27. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74: 4839-4852.
28. Wu X, Wakefield JK, Liu H, et al. Development of a novel translentiviral vector that affords predictable safety. Mol Ther 2000; 2: 47-55.
29. Kappes JC, Wu X, Wakefield JK. Prodcution of trans-lentiviral vector with predictible safety. Methods Mol Med 2003; 76: 449-465.
30. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
31. Cui Y, Iwakuma T, Chang LJ. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 1999; 73: 6171-6176.
32. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999; 261: 120-132.
33. Wang W, Qu Q, Smith FI, Kilpatrick DL. Self-inactivating lentiviruses: versatile vectors for quantitative transduction of cerebellar granule neurons and their progenitors. J Neurosci Methods 2005; 149: 144-153.
34. Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol 2004; 78: 8421-8436.
35. Ngan ES, Schillinger K, DeMayo F, Tsai SY. The mifepristoneinduciblegene regulatory system in mouse models of disease and gene therapy. Semin Cell Dev Biol 2002; 13: 143-149.
36. Parker DG, Brereton HM, Klebe S, Coster DJ, Williams KA. A steroid-inducible promoter for the cornea. Br J Ophthalmol 2009; 93: 1255-129.
37. Sirin O, Park F. Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system. Gene 2003; 323: 67-77.
38. Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 2009; 61: 527-541.
39. Brambrink T, Foreman R, Welstead GG, et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008; 2: 151-159.
40. Wu Z, Chen J, Ren J, et al. Generation of pig induced pluripotent stem cells with a drug-inducible system. J Mol Cell Biol 2009; 1: 46-54.
41. Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
42. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-5551.
43. Szulc J, Wiznerowicz M, Sauvain MO, et al. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006; 3: 109-116.
44. Baron U, Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 2000; 327: 401-421.
45. Pluta K, Diehl W, Zhang XY, et al. Lentiviral vectors encoding tetracycline-dependent repressors and transactivators for reversible knockdown of gene expression: a comparative study. BMC Biotechnol 2007; 7: 41.
46. Koponen JK, Kankkonen H, Kannasto J, et al. Doxycycline regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther 2003; 10: 459-466.
47. Semple-Rowland SL, Eccles KS, Humberstone EJ. Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters. Mol Vis 2007; 13: 2001-2011.
48. Semple-Rowland SL, Coggin WE, Geesey M, et al. Expression characteristics of dual-promoter lentiviral vectors targeting retinal photoreceptors and Muller cells. Mol Vis 2010; 16: 916-934.
49. Latta-Mahieu M, Rolland M, Caillet C, et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620.
50. Markusic DM, de Waart DR, Seppen J. Separating lentiviral vector injection and induction of gene expression in time, does not preventan immune response to rtTA in rats. PLoS One 2010; 5: e9974.
51. Pauwels K, Gijsbers R, Toelen J. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009; 9: 459-474.
52. Raben N, Lu N, Nagaraju K, et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 2001; 10: 2039-2047.
53. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumorendothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193-1206.
54. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
55. Gallo P, Grimaldi S, Latronico MV, et al. A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells. Gene Ther 2008; 15: 161-170.
56. Gruh I, Wunderlich S, Winkler M, et al. Human CMV immediateearly enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene Med 2008; 10: 21-32.
57. Zhang J, Zou L, Liu Q, et al. Rapid generation of dendritic cell specific transgenic mice by lentiviral vectors. Transgenic Res 2009; 18: 921-931.
58. Dresch C, Edelmann SL, Marconi P, Brocker T. Lentiviralmediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008; 181: 4495-506.
59. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993; 90: 8033-8037.
60. Mazarakis ND, Azzouz M, Rohll JB, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10: 2109-2121.
61. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010; 58: 107-119.
62. Connolly JB. Lentiviruses in gene therapy clinical research. Gene Ther 2002; 9: 1730-1734.
63. Rother RP, Squinto SP. The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Cell 1996; 86:185-188.
64. Russell DW, Berger MS, Miller AD. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum Gene Ther 1995; 6: 635-641.
65. DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivatedby human serum. MolTher 2000; 2: 218-222.
66. Croyle MA, Callahan SM, Auricchio A, et al. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J Virol 2004; 78: 912-921.
67. Frecha C, Costa C, Nègre D, et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviralvector pseudotyped with measles virus glycoproteins. Blood 2008; 112: 4843-4852.
68. Xu L, Mei M, Haskins ME, et al. Immune response after neonataltransfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res 2007; 120: 269-280.
69. Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr Gene Ther 2007; 7: 306-315.
70. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356.
71. Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr Gene Ther 2008: 8; 449-460.
72. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes longterm expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-3709.
73. Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007; 5: 16-24.
74. Bigger BW, Siapati EK, Mistry A, et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther 2006; 13: 117-126.
75. Chang AH, Stephan MT, Sadelain M. Stem cell derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol 2006; 24: 1017-1021.
76. Brown BD, Cantore A, Annoni A et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-4152.
77. Ramezani A, Hawley RG. Strategies to insulate lentiviral vectorexpressed transgenes. Methods Mol Biol 2010; 614: 77-100.
78. Persons DA. Lentiviral vector gene therapy: effective and safe? Mol Ther 2010; 18: 861-862.
79. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-725.
80. Xi, H, Shulha, HP, Lin, JM, Vales, et al. Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome. PLoS Genet 2007; 3: e136.
81. Hanawa H, Yamamoto M, Zhao H, Shimada T, Persons DA. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther 2009; 17: 667-674.
82. Vargas J Jr, Gusella GL, Najfeld V et al. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004; 15: 361-372.
83. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A 2006; 103: 17684-17689.
84. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009; 17: 1316-1332.
85. Apolonia L, Waddington SN, Fernandes C, et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. MolTher 2007; 15: 1947-1954.
86. Banasik MB, McCray PB, Jr. Integrase-defective lentiviral vectors: progress and applications. Gene Ther 2010; 17: 150-157.
87. Sarkis C, Philippe S, Mallet J, Serguera C. Non-integrating lentiviral vectors. Curr Gene Ther 2008; 8: 430-437.
88. Karwacz K, Mukherjee S, Apolonia L, et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 2009; 83: 3094-3103.
89. Cornu TI, Cathomen T. Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther 2007; 15: 2107-2113.
90. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrasedefective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-1306.
91. Negri DR, Michelini Z, Baroncelli S, et al. Nonintegrating lentiviral vector-based vaccine efficiently induces functional and persistent CD8+ T cell responses in mice. J Biomed Biotechnol 2010; 2010: 534501.
92. Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficientgene targeting in vivo. Proc Natl Acad Sci U S A 2001; 98: 11450-11455.
93. Lai Z, Brady RO. Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector. J Neurosci Res 2002; 67: 363-3671.
94. Tiscornia G, Tergaonkar V, Galimi F, Verma IM. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci U S A 2004; 101: 7347-7351.
95. Du ZW, Hu BY, Ayala M, Sauer B, Zhang SC. Cre recombinationmediated cassette exchange for building versatile transgenic human embryonic stem cells lines. Stem Cells 2009; 27: 1032-1041.
96. Chang CW, Lai YS, Pawlik KM, et al. Polycistronic lentiviral vector for hit and run reprogramming of adult skin fibroblasts toinduced pluripotent stem cells. Stem Cells 2009; 27: 1042-1049.
97. Mali P, Ye Z, Hommond HH, et al. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 2008; 26: 1998-2005.
98. Sommer CA, Sommer AG, Longmire TA, et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010; 28: 64-74.
99. Woltjen K, Michael IP, Mohseni P, et al. Piggybac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458: 766-770.
100. Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 2009; 6: 363-369.
101. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transducedhuman monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001; 97: 114-121.
102. Toscano MG, Delgado M, Kong W, et al. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 2010; 18: 1035-1045.
103. Trobridge GD, Wu RA, Beard BC, et al. Protection of stem cellderived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One 2009; 4: e7693.
104. Watson DJ, Karolewski BA, Wolfe JH. Stable gene delivery to CNS cells using lentiviral vectors. Methods Mol Biol 2004; 246: 413-428.
105. van Hooijdonk LW, Ichwan M, Dijkmans TF, et al. Lentivirusmediated transgene delivery to the hippocampus reveals sub-field specific differences in expression. BMC Neurosci 2009; 10: 2.
106. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-2371.
107. Pestina TI, Hargrove PW, Jay D, et al. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate highlevel expression of fetal hemoglobin. Mol Ther 2009; 17: 245-252.
108. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004; 104: 3445-3453.
109. Valori CF, Ning K, Wyles M, Azzouz M. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Curr Gene Ther 2008; 8: 406-418.
110. Lundberg C, Björklund T, Carlsson T, et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: 461-473.
111. Schambach A, Baum C. Clinical application of lentiviral vectors- concepts and practice. Curr Gene Ther 2008; 8: 474-482.
112. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for antitumor immunotherapy. Curr Gene Ther 2008; 8: 438-448.
113. Jarraya B, Boulet S, Ralph GS, et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associateddyskinesia. Sci Transl Med 2009; 1: 2ra4.
114. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
115. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson'sdisease. Ann Neurol 2003; 54: 403-414.
116. http://www.oxfordbiomedica.co.uk] Press releases of OxfordBiomedica dated 14/06/10.
117. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in Xlinked adrenoleukodystrophy. Science 2009; 326: 818-823.
118. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of betaglobin gene therapy for beta-thalassemia. Ann N Y Acad Sci 2005; 1054: 308-316.
119. Cavazzana-Calvo M, Payen E, Negre O. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010; 467: 318-322.
120. Tessio Rebello, David Stein, Gary Blick, et al. Safety and efficacy of autologous CD4+ T cells transduced with a lentiviral vector delivering anti-HIV RNA antisense env in HIV+ subjects failing one or more HAART regimens; Abstract 646; 13th Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC, May 2010.
121. Franck Lemiale, Lindsay Shovlin, Kris Andre, et al. Repeated autologous infusions of cells modified with VSV-G-pseudotypedlentiviral vector VRX496 can induce anti-VSV-G humoral response in humans without clinical consequence or effect on modifiedcells persistence: Findings from Lexgenleucel-T Phase 2 clinical trial. Abstract 41; 13th Annual Meeting of the American Society of Gene and Cell Therapy Washington, DC, May 2010.
122. Benyam Asefa, Delia Ye, Nikolay Korokhov et al. A lentiviral HIV vaccine candidate elicits long-term humoral and cellular HIVspecific immunity and minimal neutralizing activity; Abstract 165; 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Washington, DC, May 2010.
123. Shin KJ, Wall EA, Zavzavadjian JR, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci U S A 2006; 103: 13759-13764.
124. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase IIregulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005; 102: 13212-13217.
125. Singer O, Verma IM. Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther 2008; 8: 483-488.
126. Anderson JS, Javien J, Nolta JA, Bauer G. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther 2009; 17: 2103-2114.
127. Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of atriple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
128. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36ra43.
129. Li M, Li H, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci 2006; 1082: 172-179.
130. Banerjea A, Li MJ, Bauer G, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther 2003; 8: 62-71.
131. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotentstem cell lines derived from human somatic cells. Science. 2007; 318: 1917-1920.
132. Sommer CA, Stadtfeld M, Murphy GJ, et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009; 27: 543-549.
133. Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr Biol 2008; 18: 890-894.
134. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
135. Hamilton B, Feng Q, Ye M, Welstead GG. Generation of induced pluripotent stem cells by reprogramming mouse embryonic fibroblasts with a four transcription factor, doxycycline inducible lentiviral transduction system. J Vis Exp 2009; (33) p 2: 1447.
136. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454: 646
137. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321: 1218-1221.
138. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120: 3127-3136.
139. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's diseasepatient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136: 964-977.
140. Ebert AD, Yu J, Rose FF, Jr., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457: 277-280.
141. Winkler T, Cantilena A, Metais JY, et al. No evidence for clonal selection due to lentiviral integration sites in human induced pluripotent stem cells. Stem Cells 2010; 28: 687-694.